Medication Use in Rheumatoid Arthritis During Breastfeeding

General Recommendations

• The American College of Rheumatology conditionally recommends NSAIDs, including naproxen, as compatible with breastfeeding for rheumatoid arthritis management 1, 2, 3
• The American College of Rheumatology conditionally recommends against methotrexate use while breastfeeding 1, 2, 3, 4, 5, 6, 7

Medication-Specific Guidance

• Naproxen can be initiated or continued without interruption of breastfeeding, with a standard dosing regimen of 250-500 mg twice daily 1, 2
• Methotrexate may accumulate in neonatal tissues despite minimal passage into breast milk, particularly with the once-weekly dosing used in rheumatoid arthritis 1, 2, 3, 4, 5, 6, 7
• Hydroxychloroquine and sulfasalazine are strongly recommended as compatible with breastfeeding 1, 2, 3
• TNF inhibitors are strongly recommended as compatible with breastfeeding 1, 2
• Azathioprine is conditionally recommended, with negligible transfer into breast milk and infant sera 1, 2

Clinical Decision-Making

• If disease is well-controlled or mild, use naproxen alone for symptomatic management 1, 2
• If disease requires DMARD therapy, discontinue methotrexate and transition to a breastfeeding-compatible DMARD 1, 2
• Methotrexate must be discontinued before initiating breastfeeding due to tissue accumulation concerns 1, 2
• Collaboration with pediatrics is recommended when making medication decisions during lactation 1, 6
• Individual risk-benefit assessment should account for disease severity, alternative feeding options, and maternal preferences 1, 2